Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947048 · ClinicalTrials.gov registry record · Phase 2
Safety of L1-79 in Adolescent and Adult Males With Autism
A Phase 2 study, sponsored by Yamo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02947048 is a Phase 2 study that has completed, run by Yamo Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT02947048, a Phase 2 study, has completed, sponsored by Yamo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively randomized, placebo controlled patients and 5 open label patients at either 100 tid (three times daily) or 200 tid dosing for 28 days. The open label patients will be assessed for the purpose of understanding PK/PD and to determine if there are any EKG changes associated with the administration of L1-79. Additional safety information will be provided by the 30 patients randomized 2:1 active:placebo.
Interventions
- DRUG Placebo
- DRUG L1-79
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947048
The ClinicalTrials.gov registry entry for NCT02947048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yamo Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02947048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947048 about?
NCT02947048 is a clinical study titled "Safety of L1-79 in Adolescent and Adult Males With Autism". This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively randomized, placebo controlled patients and 5 open label patients at either 100 tid (three times daily) or 200 tid dosing for 28 days. The open label patients will be assessed for the purpose of understandin...
What is the current status of trial NCT02947048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-10. Estimated completion is 2018-02-01.
What interventions are being tested in trial NCT02947048?
The interventions under investigation include: Placebo (DRUG), L1-79 (DRUG).
Who is sponsoring clinical trial NCT02947048?
This trial is sponsored by Yamo Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.